Pulmonary disease, chronic obstructive Trials in Palma de Mallorca, Spain
Conditions / Pulmonary disease, chronic obstructive / Palma de Mallorca, Spain
Research into Pulmonary disease, chronic obstructive spans multiple therapeutic approaches and trial phases.
16 total trials for this combination
Showing top 10 of 16 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT00463567 | 26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | PHASE2/PHASE3 |
| NCT02105948 | Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients | COMPLETED | PHASE3 |
| NCT01313676 | Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease | COMPLETED | PHASE3 |
| NCT03345407 | Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) | TERMINATED | PHASE2 |
| NCT00975195 | Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease | COMPLETED | PHASE4 |
| NCT02164513 | A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | PHASE3 |
| NCT00144339 | Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients | COMPLETED | PHASE3 |
| NCT02296138 | Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease. | COMPLETED | PHASE3 |
| NCT02719184 | Longitudinal Follow up to Assess Biomarkers Predictive of Emphysema Progression in Patients With COPD (Chronic Obstructive Pulmonary Disease) | COMPLETED | — |
| NCT01313650 | A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD | COMPLETED | PHASE3 |